WO2022228581A1 - 1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用 - Google Patents

1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用 Download PDF

Info

Publication number
WO2022228581A1
WO2022228581A1 PCT/CN2022/091628 CN2022091628W WO2022228581A1 WO 2022228581 A1 WO2022228581 A1 WO 2022228581A1 CN 2022091628 W CN2022091628 W CN 2022091628W WO 2022228581 A1 WO2022228581 A1 WO 2022228581A1
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
virus
sorbitan
cells
Prior art date
Application number
PCT/CN2022/091628
Other languages
English (en)
French (fr)
Inventor
程功
肖小平
童良琴
Original Assignee
清华大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 清华大学 filed Critical 清华大学
Publication of WO2022228581A1 publication Critical patent/WO2022228581A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to the application of compound 1,5-sorbitan in preparing medicine for treating and preventing diseases caused by SARS-CoV-2 virus.
  • 1,5-Sorbitol is a six-carbon monosaccharide with a pyran ring structure, very similar to glucose in structure. It is mainly taken from food and distributed in various tissues and organs of the human body. Due to its stable metabolism, the content of 1,5-sorbitan can be used as one of the diagnostic criteria for diabetes, and can also be used as an indicator to detect short-term blood sugar regulation in diabetic patients, which has been used in clinical research. Since 1,5-sorbitan is stable in nature, it does not participate in cellular energy metabolism, and the human body has an automatic adjustment function for its absorption and excretion, so 1,5-sorbitan in serum is in a dynamic balance, and 1,5-sorbitan is in a dynamic balance. Alcohol is very reliable for blood glucose monitoring in diabetic patients.
  • SARS-CoV-2 also known as 2019-nCoV in the early stage, has about 80% homology with the SARS-CoV genome, and mainly causes the new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19).
  • SARS-CoV-2 belongs to the beta subgenus of coronavirus. It is a single-stranded positive-stranded RNA virus with a total length of about 30kb. It is composed of protein and RNA. Its membrane surface is mainly composed of three structural proteins: Spike Protein. , S protein), envelope protein (Envelop Protein, E protein) and membrane protein (Membrane Protein, M protein).
  • RNA nucleic acid substance responsible for viral reproduction, which is wrapped and protected by a nucleocapsid protein (Nucleoprotein, N protein).
  • Nucleoprotein, N protein a nucleocapsid protein
  • the new coronavirus epidemic has become a global pandemic and has become a serious public health problem, and there is currently no effective drug.
  • vaccines have been vaccinated, the protective ability of the vaccine is not ideal due to the continuous mutation of the virus.
  • the technical problem to be solved by the present invention is how to prepare medicines for preventing and/or treating diseases caused by SARS-CoV-2 virus or SARS-CoV-2 virus infection, and/or how to prepare SARS-CoV-2 virus inhibitors.
  • the first object of the present invention is to provide any one of the following applications of 1,5-sorbitan:
  • the disease caused by the SARS-CoV-2 virus may be a respiratory system infection and/or a digestive system infection.
  • the respiratory infection is a respiratory infection, which can be nasopharyngitis, rhinitis, pharyngitis, tracheitis and/or bronchitis, and/or a pulmonary infection, which can be pneumonia.
  • the digestive system infection can be diarrhea.
  • SARS-CoV-2 virus-infected patients present with symptoms of atypical viral pneumonia, characterized by high fever, dyspnea, lymphopenia, and rapid progression of lung shadows on chest radiographs. The virus can cause cytokine storms leading to acute lung injury, severe Patients develop acute respiratory distress syndrome and even respiratory failure.
  • the second object of the present invention is to provide the application of 1,5-sorbitan in the preparation of products for inhibiting the proliferation or replication of SARS-CoV-2 virus.
  • the third object of the present invention is to provide the application of 1,5-sorbitan in the preparation of products for inhibiting the proliferation or replication of SARS-CoV-2 virus in animal individuals, animal organs, animal tissues or animal cells.
  • the animal is a mammal.
  • the cells are human or African green monkey cells.
  • the cells may be Vero cells, Caco-2 cells or ACE2-293T cells.
  • the fourth object of the present invention is to provide a SARS-CoV-2 virus inhibitor, the active ingredient of the SARS-CoV-2 virus inhibitor contains 1,5-sorbitan.
  • the SARS-CoV-2 virus inhibitor can be only 1,5-sorbitan, and can also contain a carrier or an excipient.
  • the carrier materials here include, but are not limited to, water-soluble carrier materials (such as polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.), poorly soluble carrier materials (such as ethyl cellulose, cholesterol stearate, etc.), enteric carriers, etc. Materials (such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.). Particular among these are water-soluble carrier materials.
  • water-soluble carrier materials such as polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.
  • poorly soluble carrier materials such as ethyl cellulose, cholesterol stearate, etc.
  • enteric carriers etc.
  • Materials such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.
  • Particular among these are water-soluble carrier materials.
  • dosage forms can be prepared using these materials, including but not limited to tablets, capsules, dropping pills, aerosols, pills, powders, solutions, suspensions, emulsions,
  • diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, silicic acid Aluminum, etc.
  • wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch syrup, dextrin, syrup, honey, glucose solution, acacia mucilage, gelatin pulp, sodium carboxymethylcellulose , shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.
  • disintegrating agents such as dry starch, alginate, agar powder, alginate, sodium bicarbonate and citric acid, calcium carbon
  • the tablets can also be further prepared as coated tablets, such as sugar-coated, film-coated, enteric-coated, or bilayer and multi-layer tablets.
  • a wide variety of carriers well known in the art can be used.
  • carriers are, for example, diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oils, polyvinylpyrrolidone, Gelucire, kaolin, talc, etc.; binders such as acacia, tragacanth, gelatin, etc.
  • disintegrating agents such as agar powder, dry starch, alginate, sodium dodecyl sulfonate, methyl cellulose, ethyl cellulose, etc.
  • a wide variety of carriers well known in the art can be used. Examples of carriers are, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides and the like.
  • diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1, 3-Propanediol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and the like.
  • an appropriate amount of sodium chloride, glucose or glycerol can be added to the injection preparation, and in addition, conventional cosolvents, buffers, pH adjusters and the like can be added.
  • dosage forms can be administered by injection, including subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.; cavity administration, such as rectal and vaginal; respiratory tract administration, such as nasal cavity; mucosal administration.
  • the fifth object of the present invention is to provide a method for preparing a SARS-CoV-2 virus inhibitor, the method comprising preparing a composition using 1,5-sorbitan as a component, and the composition is SARS-CoV-2 virus inhibitor.
  • the sixth object of the present invention is to provide a medicinal compound, which is 1,5-sorbitan.
  • the medicinal compound is used for inhibiting SARS-CoV-2, or the medicinal compound is used for preventing and/or treating diseases caused by SARS-CoV-2 virus.
  • a seventh object of the present invention is to provide a method for inhibiting SARS-CoV-2 virus infection in animals, comprising administering 1,5-sorbitan to a recipient animal to inhibit SARS-CoV-2 virus infection in animals.
  • the eighth object of the present invention is to provide a method for treating or/and preventing diseases caused by SARS-CoV-2 virus, comprising administering 1,5-sorbitan to a recipient animal for treating or/and preventing SARS-CoV-2 Diseases caused by viruses.
  • Figure 1 is a graph showing the results of 1,5-sorbitan inhibiting SARS-CoV-2 virus replication in Vero cells in Example 1.
  • the data are the mean ⁇ standard deviation, and the number of replicates is 6.
  • the meaning of ** in the figure is extremely significant (P ⁇ 0.01) compared with Mock treated with 1,5-sorbitan at a concentration of 0 ⁇ M.
  • Figure 2 is a graph showing the results of 1,5-sorbitan inhibiting the proliferation of SARS-CoV-2 virus in Example 2.
  • Example 3 is a graph showing the results of the determination of the half-inhibitory concentration of 1,5-sorbitan in Example 3, the data are the mean ⁇ standard deviation, and the number of repetitions is 3.
  • Figure 4 is a graph showing the results of 1,5-sorbitan inhibiting SARS-CoV-2 virus replication in Caco-2 cells in Example 4.
  • the data are the mean ⁇ standard deviation, the number of repetitions is 6, the meaning of * in the figure is significant difference (P ⁇ 0.05), and the meaning of ** is extremely significant difference (P ⁇ 0.01).
  • Example 5 is a graph showing the results of 1,5-sorbitan inhibiting SARS-CoV-2 virus replication in ACE2-293T cells in Example 5.
  • the data are the mean ⁇ standard deviation, the number of repetitions is 6, and the meaning of ** in the figure is extremely significant (P ⁇ 0.01).
  • Figure 6 shows the result that 1,5-sorbitan in Example 6 alleviates weight loss in diabetic mice and inhibits the replication of SARS-CoV-2 virus in the lungs, trachea and turbinate.
  • Figure A in Figure 6 is the weight change of mice
  • Figure B in Figure 6 is the viral load in the lungs of mice
  • Figure C in Figure 6 is the viral load in the trachea of mice
  • Figure D in Figure 6 is the mouse turbinate virus.
  • Load weight data Body weight data are mean ⁇ SD with 7 replicates
  • viral load data are median with 7 replicates.
  • * means significant difference (P ⁇ 0.05), ** means extremely significant difference (P ⁇ 0.01), and *** means extremely significant difference (P ⁇ 0.001).
  • the experimental methods in the following examples are conventional methods unless otherwise specified.
  • the materials, reagents, etc. used in the following examples, unless otherwise specified, are conventional biochemical reagents, which can be obtained from commercial sources.
  • the SARS-CoV-2 virus in the following examples is from Shenzhen Center for Disease Control and Prevention, numbered shenzhen03, and is recorded in the non-patent document "Genomic Epidemiology of SARS-CoV-2 in Guangdongzhou, China.Cell.2020; 181 ( 5): 997-1003.e9.”.
  • the public can obtain the biological material from the applicant in accordance with the relevant regulations of the national biosafety, and the biological material is only used for repeating the relevant experiments of the present invention, and cannot be used for other purposes.
  • Vero cells in the following examples are African green monkey kidney cell lines, described in the non-patent document "Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes. Nature Microbiology, 2016, 1(9): 16087". The public can obtain the biological material from Tsinghua University, and the biological material is only used for repeating the relevant experiments of the present invention, and cannot be used for other purposes.
  • the Caco-2 cells in the following examples are colon cancer cell lines, described in the non-patent document "Proteomics of SARS-CoV-2-infected host cells Reveals therapy targets. Nature. 2020 Jul; 583(7816): 469-472 ".
  • the public can obtain the biological material from Tsinghua University, and the biological material is only used for repeating the relevant experiments of the present invention, and cannot be used for other purposes.
  • the ACE2-293T cells in the following examples are the 293T cell lines that stably integrate the ACE2 receptor, described in the non-patent document "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell .2020 Apr 16;181(2):271-280.e8”.
  • the public can obtain the biological material from Tsinghua University, and the biological material is only used for repeating the relevant experiments of the present invention, and cannot be used for other purposes.
  • 1,5-Sorbitol (product number: M1203) is a product of apexbio company, CAS chemical number: 154-58-5.
  • the DMEM complete medium supplemented with 10% FBS, 100 mg/ml streptomycin and 100 U/ml penicillin in the following examples is based on DMEM medium, supplemented with FBS (fetal bovine serum), streptomycin and penicillin.
  • DMEM medium (Cat. No. 12100046) is a product of Invitrogen.
  • the DMEM medium containing 2% serum with a final concentration of 1% low melting point agarose is based on DMEM medium, with the addition of low melting point agarose and serum, and in this medium low melting point agarose
  • the content of serum is 1% (volume percentage), and the serum content is 2% (volume percentage).
  • the RPMI1640 complete medium supplemented with 10% FBS, 100 mg/ml streptomycin and 100 U/ml penicillin is based on the RPMI1640 complete medium, supplemented with FBS (fetal bovine serum), streptomycin and penicillin In this medium, the content of FBS is 10% (volume percentage), the concentration of streptomycin is 100 mg/ml, and the concentration of penicillin is 100 U/ml.
  • FBS fetal bovine serum
  • streptomycin fetal bovine serum
  • penicillin 100 U/ml.
  • RPMI1640 (article number: 21875034) is a product of Invitrogen.
  • Example 1 1,5-Sorbitol inhibits SARS-CoV-2 virus replication in Vero cells
  • 1,5-sorbitan was set to 0 ⁇ M (Mock), 100 ⁇ M (treatment one), 200 ⁇ M (treatment two)
  • the specific steps are as follows:
  • the Vero cell line was cultured in a constant temperature incubator at 37°C, 5% CO 2 , using DMEM complete medium supplemented with 10% FBS and 100 mg/ml streptomycin and 100 U/ml penicillin. Well-grown Vero cells were seeded in a 48-well plate at a cell density of 1 ⁇ 10 4 cells/ml.
  • 1,5-sorbitan solution the solvent is DMSO, the solute is 1,5-sorbitan
  • the concentration of 1,5-sorbitan in treatment one culture system is 100 ⁇ M
  • 1,5-sorbitan concentration in treatment two culture system is 200 ⁇ M
  • 1,5-sorbitan in treatment two culture system The concentration in the three-culture system was 300 ⁇ M
  • the concentration of 1,5-sorbitan in the treatment four-culture system was 400 ⁇ M.
  • RNA with RNA extraction kit product number AP-MN-MS-RNA-250, product of Axygen company
  • reverse-transcribe the RNA with reverse transcription kit product of Bio-Rad company
  • SYBR Green qPCR technology was used to detect the viral load in the samples, and the GAPDH value was used as an internal reference.
  • the primer pairs used to detect SARS-CoV-2 are as follows:
  • Upstream primer 5'-AGAAGATTGGTTAGATGATGATAGT-3' (as shown in sequence listing sequence 1);
  • Downstream primer 5'-TTCCATCTCTAATTGAGGTTGAACC-3' (as shown in Sequence Listing Sequence 2).
  • the primer pairs used to detect the GAPDH gene are as follows:
  • Upstream primer 5'-AGCCTCAAGATCATCAGCAATG-3' (as shown in sequence listing sequence 3);
  • Downstream primer 5'-ATGGACTGTGGTCATGAGTCCTT-3' (as shown in Sequence Listing Sequence 4).
  • Example 2 1,5-Sorbitol inhibits SARS-CoV-2 virus proliferation (immunofluorescence)
  • 1,5-sorbitan was set to 0 ⁇ M (Mock), 100 ⁇ M (treatment one), 200 ⁇ M (treatment two)
  • the specific steps are as follows:
  • the washed and sterilized glass slides were placed in a 24-well plate in advance, and 1 mL of DMEM complete medium supplemented with 10% FBS, 100 mg/ml streptomycin and 100 U/ml penicillin was added to each well.
  • Vero cells (0.5-2) x 103 were seeded so that they were fully adherent at the time of infection and the cell density reached 50-60%. Vero cells were cultured in a constant temperature incubator at 37 °C, 5% CO .
  • blocking solution BD, 51-2091KZ
  • Example 3 1,5-sorbitan half-inhibitory concentration (IC 50 ) determination
  • the half-inhibitory concentration (IC 50 ) of 1,5-sorbitan was determined, and 1,5-sorbitan was set to 400 ⁇ M, 300 ⁇ M, 200 ⁇ M, 100 ⁇ M, 50 ⁇ M, 25 ⁇ M, 12.5 ⁇ M, 6.25 ⁇ M, 3.125 ⁇ M, a total of 9 Concentration gradient, the specific steps are as follows:
  • the Vero cell line was cultured in a constant temperature incubator at 37° C., 5% CO 2 , and the medium was DMEM complete medium supplemented with 10% FBS and 100 mg/ml streptomycin and 100 U/ml penicillin. Well-grown Vero cells were seeded in a 48-well plate at a cell density of 1 ⁇ 10 4 cells/ml.
  • the SARS-CoV-2 virus was inoculated into the cells at 0.001 MOI, the corresponding concentration of DMSO was used as a control, and incubated for 2 h in a constant temperature incubator at 37 °C, 5% CO 2 . Three replicates were set for each concentration of treatment and each concentration of control.
  • the well-grown Vero cells were seeded in a 6-well plate with a cell density of 4.5 ⁇ 10 5 /ml, and the medium was completely cultured in DMEM supplemented with 10% FBS, 100mg/ml streptomycin and 100U/ml penicillin base. Incubate overnight in a 37°C, 5% CO 2 incubator.
  • 1,5-sorbitan was set to 0 ⁇ M (Mock), 100 ⁇ M (treatment one), 200 ⁇ M (treatment one) 2), 300 ⁇ M (treatment 3), 400 ⁇ M (treatment 4), a total of 5 concentration gradient treatments, the specific steps are as follows:
  • the SARS-CoV-2 virus was inoculated into the cells at 0.001 MOI, the corresponding concentration of DMSO was used as a control, and incubated for 2 h in a constant temperature incubator at 37 °C, 5% CO 2 . Six replicates were set up for each concentration of treatment and each concentration of control.
  • RNA with RNA extraction kit product number AP-MN-MS-RNA-250, product of Axygen company
  • reverse-transcribe the RNA with reverse transcription kit product of Bio-Rad company
  • SYBR Green qPCR technology was used to detect the viral load in the samples, and the GAPDH value was used as an internal reference.
  • the primer pairs used to detect SARS-CoV-2 are as follows:
  • Upstream primer 5'-AGAAGATTGGTTAGATGATGATAGT-3' (as shown in sequence listing sequence 1);
  • Downstream primer 5'-TTCCATCTCTAATTGAGGTTGAACC-3' (as shown in Sequence Listing Sequence 2).
  • the primer pairs used to detect the GAPDH gene are as follows:
  • Upstream primer 5'-AGCCTCAAGATCATCAGCAATG-3' (as shown in sequence listing sequence 3);
  • Downstream primer 5'-ATGGACTGTGGTCATGAGTCCTT-3' (as shown in Sequence Listing Sequence 4).
  • Example 5 1,5-sorbitan inhibits SARS-CoV-2 virus replication in ACE2-293T cells
  • 1,5-sorbitan was set to 0 ⁇ M (Mock), 100 ⁇ M (treatment one), 200 ⁇ M (treatment one) 2), 300 ⁇ M (treatment 3), 400 ⁇ M (treatment 4), a total of 5 concentration gradient treatments, the specific steps are as follows:
  • ACE2-293T cell line (1) Cultivate the ACE2-293T cell line in a constant temperature incubator at 37°C, 5% CO 2 , using DMEM complete medium supplemented with 10% FBS and 100 mg/ml streptomycin and 100 U/ml penicillin.
  • ACE2-293T cells with good growth status were seeded in 48-well plates, and the cell density was 1 ⁇ 10 4 /ml.
  • the SARS-CoV-2 virus was inoculated into ACE2-293T cells at 0.0001 MOI, the corresponding concentration of DMSO was used as a control, and incubated for 2 h in a constant temperature incubator at 37°C, 5% CO 2 . Six replicates were set up for each concentration of treatment and each concentration of control.
  • RNA with RNA extraction kit product number AP-MN-MS-RNA-250, product of Axygen company
  • reverse-transcribe the RNA with reverse transcription kit product of Bio-Rad company
  • SYBR Green qPCR technology was used to detect the viral load in the samples, and the GAPDH value was used as an internal reference.
  • the primer pairs used to detect SARS-CoV-2 are as follows:
  • Upstream primer 5'-AGAAGATTGGTTAGATGATGATAGT-3' (as shown in sequence listing sequence 1);
  • Downstream primer 5'-TTCCATCTCTAATTGAGGTTGAACC-3' (as shown in Sequence Listing Sequence 2).
  • the primer pairs used to detect the GAPDH gene are as follows:
  • Upstream primer 5'-AGCCTCAAGATCATCAGCAATG-3' (as shown in sequence listing sequence 3);
  • Downstream primer 5'-ATGGACTGTGGTCATGAGTCCTT-3' (as shown in Sequence Listing Sequence 4).
  • Example 6 1,5-Sorbitol inhibits SARS-CoV-2 virus replication in a mouse model
  • mice were nasally infected with 8000 PFU of the new coronavirus mouse-adapted strain MASCp36.
  • mice were euthanized on the third day after infection, and the lungs, trachea and turbinates were taken for the detection of viral load.
  • Each 20 mg of tissue was added to 400 ⁇ l of RI solution, thoroughly ground and frozen at -80°C.
  • RNA with RNA extraction kit product number AP-MN-MS-RNA-250, product of Axygen company
  • reverse-transcribe the RNA with reverse transcription kit product of Bio-Rad company
  • SYBR Green qPCR technology was used to detect the viral load in the samples, and the GAPDH value was used as an internal reference.
  • the primer pairs used to detect SARS-CoV-2 are as follows:
  • Upstream primer 5'-AGAAGATTGGTTAGATGATGATAGT-3' (as shown in sequence listing sequence 1);
  • Downstream primer 5'-TTCCATCTCTAATTGAGGTTGAACC-3' (as shown in Sequence Listing Sequence 2).
  • the primer pairs used to detect the GAPDH gene are as follows:
  • Upstream primer 5'-TCAACAGCAACTCCCACTCTTCCA-3' (as shown in sequence listing sequence 3);
  • Downstream primer 5'-ACCCTGTTGCTGTAGCCGTATTCA-3' (as shown in Sequence Listing Sequence 4).
  • 1,5-sorbitan can As a candidate drug for the prevention and treatment of SARS-CoV-2 virus infection.
  • the invention has application value for the treatment of infected SARS-CoV-2 virus.
  • 1,5-sorbitan can be used as As a candidate drug for the prevention and treatment of SARS-CoV-2 virus infection
  • 1,5-sorbitan has value in application as a candidate drug for the prevention and treatment of SARS-CoV-2 virus infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供化合物1,5-脱水山梨醇在制备SARS-CoV-2病毒所致疾病药物中的应用。本发明通过对1,5-脱水山梨醇分别在Vero细胞、Caco-2细胞、ACE2-293T细胞中对SARS-CoV-2病毒的抑制效果的研究，发现了1,5-脱水山梨醇可作为SARS-CoV-2病毒感染的防治候选药物。本发明对感染SARS-CoV-2病毒的治疗具有应用价值。

Description

1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用 技术领域
本发明涉及化合物1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用。
背景技术
1,5-脱水山梨醇是一种具有吡喃环结构的六碳单糖，在结构上与葡萄糖十分相似，主要从食物中摄取，分布在人体的各个组织和器官。由于它代谢稳定，1,5-脱水山梨醇的含量可作为糖尿病的诊断标准之一，也可作为检测糖尿病患者短期内血糖调控的指标，已被应用于临床研究。由于1,5-脱水山梨醇性质稳定，不参与细胞能量代谢，且人体对其吸收和排泄有自动调节功能，因此血清中1,5-脱水山梨醇处于动态平衡中，1,5-脱水山梨醇用于糖尿病患者血糖监控十分可靠。
新型冠状病毒(SARS-CoV-2)早期也被称为2019-nCoV，与SARS-CoV基因组的同源性约为80％，主要引起新型冠状病毒肺炎(Corona Virus Disease 2019，COVID-19)。SARS-CoV-2隶属冠状病毒的β亚属，为单股正链的RNA病毒，全长约30kb，由蛋白质和RNA组成，其膜表面主要由3种结构蛋白组成：刺突蛋白(Spike Protein，S蛋白)、包膜蛋白(Envelop Protein，E蛋白)和膜蛋白(Membrane Protein，M蛋白)。病毒里面是负责病毒繁殖的核酸物质RNA，它由核衣壳蛋白(Nucleoprotein，N蛋白)包裹并保护着。新冠病毒疫情在全球大流行，已成为一个严重的公共健康问题，目前还没有特效药物。虽然已有疫苗进行接种，但是由于病毒持续的突变，导致疫苗的保护能力不够理想。
目前急需研发能够治疗SARS-CoV-2病毒所致疾病的药物。
发明公开
本发明所要解决的技术问题是如何制备预防和/或治疗SARS-CoV-2病毒所致疾病或SARS-CoV-2病毒感染的药物，和/或如何制备SARS-CoV-2病毒抑制剂。
为了解决以上技术问题，本发明的第一个目的是提供1,5-脱水山梨醇的下述任一种应用：
U1、1,5-脱水山梨醇在制备预防和/或治疗SARS-CoV-2病毒所致疾病或SARS-CoV-2病毒感染的药物中的应用；
U2、1,5-脱水山梨醇在制备SARS-CoV-2病毒抑制剂中的应用。
上述应用中，所述SARS-CoV-2病毒所致疾病可为呼吸系统感染和/或消化系统感染。所述呼吸系统感染为呼吸道感染和/或肺部感染，所述呼吸道感染可为鼻咽炎、鼻炎、咽喉炎、气管炎和/或支气管炎，所述肺部感染可为肺炎。所述消化系统感染可为腹泻。SARS-CoV-2病毒感染的患者表现出非典型病毒性肺炎症状，特征为高烧，呼吸困难，淋巴细胞减少，胸片可见肺部阴影进展迅速，病毒会引起细胞因子风暴导致急性肺损伤，重症患者出现急性呼吸窘迫综合征，甚至呼吸衰竭。
本发明的第二个目的是提供1,5-脱水山梨醇在制备抑制SARS-CoV-2病毒增殖或复制产品中的应用。
本发明的第三个目的是提供1,5-脱水山梨醇在制备抑制动物个体、动物器官、动物组织或动物细胞中SARS-CoV-2病毒增殖或复制产品中的应用。
上述应用中，所述动物为哺乳动物。
上述应用中，所述细胞为人或非洲绿猴细胞。所述细胞可为Vero细胞、Caco-2细胞或ACE2-293T细胞。
本发明的第四个目的是提供SARS-CoV-2病毒抑制剂，所述SARS-CoV-2病毒抑制剂的活性成分含有1,5-脱水山梨醇。
所述SARS-CoV-2病毒抑制剂可只为1,5-脱水山梨醇，也可还含有载体或赋形剂。
这里的载体材料包括但不限于水溶性载体材料(如聚乙二醇、聚乙烯吡咯烷酮、有机酸等)、难溶性载体材料(如乙基纤维素、胆固醇硬脂酸酯等)、肠溶性载体材料(如醋酸纤维素酞酸酯和羧甲乙纤维素等)。其中具体的是水溶性载体材料。使用这些材料可以制成多种剂型，包括但不限于片剂、胶囊、滴丸、气雾剂、丸剂、粉剂、溶液剂、混悬剂、乳剂、颗粒剂、脂质体、透皮剂、口含片、栓剂、冻干粉针剂等。可以是普通制剂、缓释制剂、控释制剂及各种微粒给药系统。为了将单位给药剂型制成片剂，可以广泛使用本领域公知的各种载体。关于载体的例子是，例如稀 释剂与吸收剂，如淀粉、糊精、硫酸钙、乳糖、甘露醇、蔗糖、氯化钠、葡萄糖、尿素、碳酸钙、白陶土、微晶纤维素、硅酸铝等；湿润剂与粘合剂，如水、甘油、聚乙二醇、乙醇、丙醇、淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、紫胶、甲基纤维素、磷酸钾、聚乙烯吡咯烷酮等；崩解剂，例如干燥淀粉、海藻酸盐、琼脂粉、褐藻淀粉、碳酸氢钠与枸橼酸、碳酸钙、聚氧乙烯、山梨糖醇脂肪酸酯、十二烷基磺酸钠、甲基纤维素、乙基纤维素等；崩解抑制剂，例如蔗糖、三硬脂酸甘油酯、可可脂、氢化油等；吸收促进剂，例如季铵盐、十二烷基硫酸钠等；润滑剂，例如滑石粉、二氧化硅、玉米淀粉、硬脂酸盐、硼酸、液体石蜡、聚乙二醇等。还可以将片剂进一步制成包衣片，例如糖包衣片、薄膜包衣片、肠溶包衣片，或双层片和多层片。为了将单位给药剂型制成丸剂，可以广泛使用本领域公知的各种载体。关于载体的例子是，例如稀释剂与吸收剂，如葡萄糖、乳糖、淀粉、可可脂、氢化植物油、聚乙烯吡咯烷酮、Gelucire、高岭土、滑石粉等；粘合剂如阿拉伯胶、黄蓍胶、明胶、乙醇、蜂蜜、液糖、米糊或面糊等；崩解剂，如琼脂粉、干燥淀粉、海藻酸盐、十二烷基磺酸钠、甲基纤维素、乙基纤维素等。为了将单位给药剂型制成栓剂，可以广泛使用本领域公知的各种载体。关于载体的例子是，例如聚乙二醇、卵磷脂、可可脂、高级醇、高级醇的酯、明胶、半合成甘油酯等。为了将单位给药剂型制成注射用制剂，如溶液剂、乳剂、冻干粉针剂和混悬剂，可以使用本领域常用的所有稀释剂，例如，水、乙醇、聚乙二醇、1,3-丙二醇、乙氧基化的异硬脂醇、多氧化的异硬脂醇、聚氧乙烯山梨醇脂肪酸酯等。另外，为了制备等渗注射液，可以向注射用制剂中添加适量的氯化钠、葡萄糖或甘油，此外，还可以添加常规的助溶剂、缓冲剂、pH调节剂等。此外，如需要，也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂、甜味剂或其它材料。使用上述剂型可以经注射给药，包括皮下注射、静脉注射、肌肉注射和腔内注射等；腔道给药，如经直肠和阴道；呼吸道给药，如经鼻腔；粘膜给药。
本发明的第五个目的是提供制备SARS-CoV-2病毒抑制剂的方法，所述方法包括将1,5-脱水山梨醇作为组分制备组合物，所述组合物为SARS-CoV-2病毒抑制剂。
本发明的第六个目的是提供药用化合物，所述药用化合物为1,5-脱水山梨醇。
所述药用化合物用于抑制SARS-CoV-2，或所述药用化合物用于预防和/或治疗SARS-CoV-2病毒所致疾病。
本发明的第七个目的是提供抑制SARS-CoV-2病毒感染动物的方法，包括给受体动物施用1,5-脱水山梨醇以抑制SARS-CoV-2病毒感染动物。
本发明的第八个目的是提供治疗或/和预防SARS-CoV-2病毒所致疾病的方法，包括给受体动物施用1,5-脱水山梨醇进行治疗或/和预防SARS-CoV-2病毒所致疾病。
附图说明
图1为实施例1中1,5-脱水山梨醇在Vero细胞抑制SARS-CoV-2病毒复制结果图。数据为平均值±标准差，重复数为6，图中**的含义为与1,5-脱水山梨醇处理浓度为0μM的Mock相比，差异极显著(P<0.01)。
图2为实施例2中1,5-脱水山梨醇抑制SARS-CoV-2病毒增殖的结果图。
图3为实施例3中1,5-脱水山梨醇半抑制浓度测定结果图，数据为平均值±标准差，重复数为3。
图4为实施例4中1,5-脱水山梨醇在Caco-2细胞抑制SARS-CoV-2病毒复制结果图。数据为平均值±标准差，重复数为6，图中*的含义为差异显著(P<0.05)，**的含义为差异极显著(P<0.01)。
图5为实施例5中1,5-脱水山梨醇在ACE2-293T细胞抑制SARS-CoV-2病毒复制结果图。数据为平均值±标准差，重复数为6，图中**的含义为差异极显著(P<0.01)。
图6位实施例6中1,5-脱水山梨醇在糖尿病小鼠中缓解体重减轻，抑制SARS-CoV-2病毒在肺部、气管、鼻甲复制的结果图。其中，图6的A图为小鼠体重变化，图6的B图为小鼠肺部病毒载量，图6的C图为小鼠气管病毒载量，图6的D图为小鼠鼻甲病毒载量体重数据。体重数据为平均值±标准差，重复数为7，病毒载量数据为中位数，重复数为7。图中*的含义为差异显著(P<0.05)，**的含义为差异极显著(P<0.01)，***的含义为差异特别显著(P<0.001)。
实施发明的最佳方式
下面结合具体实施方式对本发明进行进一步的详细描述，给出的实施例仅为了阐明本发明，而不是为了限制本发明的范围。以下提供的实施例可作为本技术领域普通技术人员进行进一步改进的指南，并不以任何方式构成对本发明的限制。
下述实施例中的实验方法，如无特殊说明，均为常规方法。下述实施例中所用的材料、试剂等，如无特殊说明，均为常规生化试剂，可从商业途径得到。
下述实施例中的SARS-CoV-2病毒来自深圳市疾病预防控制中心，编号为shenzhen03，记载于非专利文献“Genomic Epidemiology of SARS-CoV-2 in Guangdong Province,China.Cell.2020；181(5):997-1003.e9.”。公众按照国家生物安全的有关规定可从申请人获得该生物材料，该生物材料只为重复本发明的相关实验所用，不可作为其它用途使用。
下述实施例中的Vero细胞为非洲绿猴肾细胞系，记载于非专利文献“Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes.Nature Microbiology,2016,1(9):16087”。公众可从清华大学获得该生物材料，该生物材料只为重复本发明的相关实验所用，不可作为其它用途使用。
下述实施例中的Caco-2细胞为结肠癌细胞系，记载于非专利文献“Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature.2020 Jul；583(7816):469-472”。公众可从清华大学获得该生物材料，该生物材料只为重复本发明的相关实验所用，不可作为其它用途使用。
下述实施例中的ACE2-293T细胞为稳定整合ACE2受体的293T细胞系，记载于非专利文献“SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Cell.2020 Apr 16；181(2):271-280.e8”。公众可从清华大学获得该生物材料，该生物材料只为重复本发明的相关实验所用，不可作为其它用途使用。
1,5-脱水山梨醇(货号：M1203)为apexbio公司产品，CAS化学号：154-58-5。
下述实施例中添加10％FBS及100mg/ml链霉素和100U/ml青霉素的DMEM完全培养基是以DMEM培养基为基础培养基，添加FBS(胎牛血清)、链霉素和青霉素的培养基，在该培养基中FBS的含量为10％(体积百分含量)，链霉素的浓度为100mg/ml，青霉素的浓度为100U/ml。DMEM培养基(货号12100046)为invitrogen公司产品。
下述实施例中终浓度为1％低熔点琼脂糖的含2％血清的DMEM培养基是以DMEM培养基为基础培养基，添加低熔点琼脂糖和血清，在该培养基中低熔点琼脂糖的含量为1％(体积百分含量)，血清的含量为2％(体积百分含量)。
下述实施例中添加10％FBS及100mg/ml链霉素和100U/ml青霉素的RPMI1640完全培养基是以RPMI1640完全培养基为基础培养基，添加FBS(胎牛血清)、链霉素和青霉素的培养基，在该培养基中FBS的含量为10％(体积百分含量)，链霉素的浓度为100mg/ml，青霉素的浓度为100U/ml。RPMI1640(货号：21875034)为invitrogen公司产品。
下述实施例中的定量试验，如无特别说明，均设置三次重复实验，结果取平均值。下述实施例中的所有数据均采用GraphPad\Prism 7软件Student’s T-test进行显著性分析。
实施例1：1,5-脱水山梨醇在Vero细胞抑制SARS-CoV-2病毒复制
本实施例研究1,5-脱水山梨醇在Vero细胞中对SARS-CoV-2病毒复制的影响，1,5-脱水山梨醇设置0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)共5个浓度梯度的处理，具体步骤如下：
(1)在37℃，5％CO 2的恒温培养箱中培养Vero细胞系，培养基用添加10％FBS及100mg/ml链霉素和100U/ml青霉素的DMEM完全培养基。将生长状态良好的Vero细胞种于48孔板中，细胞密度为1×10 4个/ml。
(2)感染病毒之前提前1h在Mock孔中加入200μl细胞培养基稀释的DMSO(二甲基亚砜)，得到Mock培养体系，使1,5-脱水山梨醇在Mock培养体系中的浓度为0μM。在其余各孔中分别加入200μl的1,5-脱水山梨醇溶液(溶剂为DMSO，溶质为1,5-脱水山梨醇)，分别得到处理一培养体系、处理二培养体系、处理三培养体系和处理四培养体系，1,5-脱水山 梨醇在处理一培养体系中的浓度为100μM，1,5-脱水山梨醇在处理二培养体系中的浓度为200μM，1,5-脱水山梨醇在处理三培养体系中的浓度为300μM，1,5-脱水山梨醇在处理四培养体系中的浓度为400μM。
(3)将SARS-CoV-2病毒按0.001M.O.I(即MOI＝0.001)接种到Vero细胞中，37℃，5％CO 2的恒温培养箱中孵育2h。每个浓度的处理和每个浓度的对照均设置6个重复。
(4)去掉细胞上清，用PBS缓冲液冲洗细胞三次，最后一次时吸干残留的PBS。加入400μl的1,5-脱水山梨醇溶液(溶剂为DMSO，溶质为1,5-脱水山梨醇，用培养基稀释到特定浓度)，使各培养体系中的1,5-脱水山梨醇的浓度分别为0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)。37℃，5％CO 2的恒温培养箱中继续培养40h。
(5)去掉细胞上清，用PBS冲洗细胞三次，每孔加入400μl RI溶液(公司：Axygen,货号AP-MN-MS-RNA-250)，充分裂解细胞后，转移到1.5ml离心管中，-80℃冻存。
(6)取冻存的样品，用RNA提取试剂盒(货号AP-MN-MS-RNA-250，Axygen公司产品)提取RNA并用反转录试剂盒(Bio-Rad公司产品)将RNA反转录为cDNA。
(7)利用SYBR Green qPCR技术检测样品中的病毒载量，GAPDH值作为内参。计算公式如下：SARS-CoV-2/GAPDH mRNA Ratio＝2 (内参的Ct值-病 毒的Ct值)。
用于检测SARS-CoV-2的引物对如下：
上游引物：5’-AGAAGATTGGTTAGATGATGATAGT-3’(如序列表序列1所示)；
下游引物：5’-TTCCATCTCTAATTGAGGTTGAACC-3’(如序列表序列2所示)。
用于检测GAPDH基因的引物对如下：
上游引物：5’-AGCCTCAAGATCATCAGCAATG-3’(如序列表序列3所示)；
下游引物：5’-ATGGACTGTGGTCATGAGTCCTT-3’(如序列表序列4所示)。
结果如图1所示：与对照组相比，加入1,5-脱水山梨醇的Vero细胞病毒载量明显下降，且呈现剂量依赖性。
实施例2：1,5-脱水山梨醇抑制SARS-CoV-2病毒增殖(免疫荧光)
本实施例研究1,5-脱水山梨醇在Vero细胞中对SARS-CoV-2病毒增殖的影响，1,5-脱水山梨醇设置0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)共5个浓度梯度的处理，具体步骤如下：
(1)预先将洗干净灭菌的玻片置于24孔板内，每孔加入1mL添加10％FBS及100mg/ml链霉素和100U/ml青霉素的DMEM完全培养基。接种Vero细胞(0.5-2)×10 3个，使其在感染时完全贴壁，且细胞密度达50-60％。在37℃，5％CO 2的恒温培养箱中培养Vero细胞。
(2)感染病毒之前提前1h在各孔加入200μl的细胞培养基稀释的1,5-脱水山梨醇溶液，使1,5-脱水山梨醇在Mock的培养体系中的浓度为0μM，在处理一的培养体系中的浓度为100μM、在处理二的培养体系中的浓度为200μM、在处理三的培养体系中的浓度为300μM、在处理四的培养体系中的浓度为400μM。
(3)将SARS-CoV-2病毒按0.001M.O.I.(即MOI＝0.001)接种到Vero细胞中，相应浓度的培养基稀释后的DMSO(二甲基亚砜)溶液作为对照，37℃，5％CO 2的恒温培养箱中孵育2h。每个浓度的处理和每个浓度的对照均设置3个重复。
(4)去掉细胞上清，用PBS缓冲液冲洗细胞三次，最后一次时吸干残留的PBS。加入400μl的1,5-脱水山梨醇溶液，浓度分别为0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)的1,5-脱水山梨醇溶液，继续培养40h。
(5)去掉细胞上清，用PBS洗3遍，向24孔板加入1mL的4％新鲜配制的多聚甲醛作为固定液，常温固定60min。去固定液，用洗涤液洗3次，每次3-5min，吸尽液体。
(6)用2mL封闭液(BD,51-2091KZ)封闭15min，可以在摇床上轻微摇动。去封闭液，用洗涤液洗3次，每次3-5min，吸尽液体。
(7)加入一抗(Anti-SARS-CoV-2Nucleocapsid，abcam公司产品， 货号ab272852)孵育2h，用PBST洗3遍，去上清，用PBST洗3遍，加入cy3标记的二抗(invitrogen公司产品，货号A-11003)和DAPI(abcam公司产品，货号ab228549)，37℃孵育1h。
(8)吸弃上清，加入PBST洗3次，每次3-5min，吸尽液体。将盖玻片取出置于干净纸巾上，加20μL抗淬灭剂于载玻片上，将玻片细胞面朝下，放置于避免气泡产生。等玻片周围干燥后，在玻片边缘加20μL中性树胶封片，将玻片放置于荧光显微镜下观察，并拍照。
结果如图2所示：加入了1,5-脱水山梨醇的实验组发荧光的细胞数量明显少于对照组。
实施例3：1,5-脱水山梨醇半抑制浓度(IC 50)测定
本实施例测定1,5-脱水山梨醇半抑制浓度(IC 50)，1,5-脱水山梨醇设置400μM，300μM，200μM，100μM，50μM，25μM，12.5μM，6.25μM，3.125μM共9个浓度梯度，具体步骤如下：
(1)以DMSO作为溶剂，用细胞培养基稀释将1,5-脱水山梨醇分别配制成400μM，300μM，200μM，100μM，50μM，25μM，12.5μM，6.25μM，3.125μM的溶液。
(2)在37℃，5％CO 2的恒温培养箱中培养Vero细胞系，培养基用添加10％FBS及100mg/ml链霉素和100U/ml青霉素的DMEM完全培养基。将生长状态良好的Vero细胞种于48孔板中，细胞密度为1×10 4个/ml。
(3)感染病毒之前提前1h在各孔加入200μl的1,5-脱水山梨醇溶液，使1,5-脱水山梨醇的终浓度分别为400μM，300μM，200μM，100μM，50μM，25μM，12.5μM，6.25μM，3.125μM。
(4)将SARS-CoV-2病毒按0.001M.O.I.接种到细胞中，相应浓度的DMSO作为对照，37℃，5％CO 2的恒温培养箱中孵育2h。每个浓度的处理和每个浓度的对照均设置3个重复。
(6)去掉细胞上清，用PBS冲洗细胞三次，最后一次时吸干残留的PBS。各浓度的处理加入上述步骤(1)配好的对应浓度的1,5-脱水山梨醇溶液，继续培养40h。细胞上清转移到1.5ml离心管中，-80℃冻存。
(7)将生长状态良好的Vero细胞种于6孔板中，细胞密度为4.5×10 5/ml，培养基用添加10％FBS及100mg/ml链霉素和100U/ml青霉素 的DMEM完全培养基。37℃，5％CO 2培养箱培养过夜。
(8)将上述步骤(6)得到的细胞上清分别稀释100倍，1000倍，10000倍，加入6孔板，与Vero细胞于37℃孵育2小时。
(9)去掉细胞上清，并用PBS洗一遍，每孔加入2.5ml配好的终浓度为1％低熔点琼脂糖的含2％血清的DMEM培养基，并将孔板室温放置20分钟，让凝胶培养基充分凝固。
(10)将凝固后的6孔板放回37℃，5％CO 2培养箱中继续培养3-4天。通过显微镜观测，有明显细胞裂解的空斑形成时，在每孔中加入1ml 4％的甲醛溶液，室温固定1小时。
(11)待细胞固定好后，抠出板孔中的凝胶，用水洗掉剩余的甲醛溶液，再向每孔中加入500μl 1％的结晶紫溶液，室温染色5分钟。
(12)弃去结晶紫染料，用水反复冲掉剩余的结晶紫，在吸水纸上扣干多于水分，正面放置晾干。
计算、数每孔中的空斑数量。使用GraphPad\Prism 7软件进行IC50作图和分析。结果见图3：IC 50＝27.44μM。
实施例4：1,5-脱水山梨醇在Caco-2细胞抑制SARS-CoV-2病毒复制
本实施例研究1,5-脱水山梨醇在Caco-2细胞中对SARS-CoV-2病毒复制的影响，1,5-脱水山梨醇设置0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)共5个浓度梯度的处理，具体步骤如下：
(1)在37℃，5％CO 2的恒温培养箱中培养Caco-2细胞系，培养基用添加10％FBS及100mg/ml链霉素和100U/ml青霉素的RPMI1640完全培养基。将生长状态良好的Caco-2细胞种于48孔板中，Caco-2细胞密度为1×10 4/ml。
(2)感染病毒之前提前1h加入200μl细胞培养基稀释的1,5-脱水山梨醇溶液，使1,5-脱水山梨醇在Mock中的终浓度为0μM，在处理一中的终浓度为100μM、在处理二中的终浓度为200μM、在处理三中的终浓度为300μM、在处理四中的终浓度为400μM。
(3)将SARS-CoV-2病毒按0.001M.O.I接种到细胞中，相应浓度的DMSO作为对照，37℃，5％CO 2的恒温培养箱中孵育2h。每个浓度的处理 和每个浓度的对照均设置6个重复。
(4)去掉细胞上清，用PBS冲洗细胞三次，最后一次时吸干残留的PBS。加入400μl的1,5-脱水山梨醇溶液，浓度分别为0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)。37℃，5％CO 2的恒温培养箱中继续培养40h。
(5)去掉细胞上清，用PBS冲洗细胞三次，每孔加入400μl RI溶液，充分裂解细胞后，转移到1.5ml离心管中，-80℃冻存。
(6)取冻存的样品，用RNA提取试剂盒(货号AP-MN-MS-RNA-250，Axygen公司产品)提取RNA并用反转录试剂盒(Bio-Rad公司产品)将RNA反转录为cDNA。
(7)利用SYBR Green qPCR技术检测样品中的病毒载量，GAPDH值作为内参。计算公式如下：SARS-CoV-2/GAPDH mRNA Ratio＝2 (内参的Ct值-病 毒的Ct值)。
用于检测SARS-CoV-2的引物对如下：
上游引物：5’-AGAAGATTGGTTAGATGATGATAGT-3’(如序列表序列1所示)；
下游引物：5’-TTCCATCTCTAATTGAGGTTGAACC-3’(如序列表序列2所示)。
用于检测GAPDH基因的引物对如下：
上游引物：5’-AGCCTCAAGATCATCAGCAATG-3’(如序列表序列3所示)；
下游引物：5’-ATGGACTGTGGTCATGAGTCCTT-3’(如序列表序列4所示)。
结果如图4所示：与对照组相比，加入1,5-脱水山梨醇的Caco-2细胞病毒载量明显下降。
实施例5：1,5-脱水山梨醇在ACE2-293T细胞抑制SARS-CoV-2病毒复制
本实施例研究1,5-脱水山梨醇在ACE2-293T细胞中对SARS-CoV-2病毒复制的影响，1,5-脱水山梨醇设置0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)共5个浓度梯度 的处理，具体步骤如下：
(1)在37℃，5％CO 2的恒温培养箱中培养ACE2-293T细胞系，培养基用添加10％FBS及100mg/ml链霉素和100U/ml青霉素的DMEM完全培养基。将生长状态良好的ACE2-293T细胞种于48孔板中，细胞密度为1×10 4/ml。
(2)感染病毒之前提前1h在各孔加入200μl细胞培养基稀释的1,5-脱水山梨醇溶液，使1,5-脱水山梨醇在Mock中的终浓度为0μM，在处理一中的终浓度为100μM、在处理二中的终浓度为200μM、在处理三中的终浓度为300μM、在处理四中的终浓度为400μM。
(3)将SARS-CoV-2病毒按0.0001M.O.I接种到ACE2-293T细胞中，相应浓度的DMSO作为对照，37℃，5％CO 2的恒温培养箱中孵育2h。每个浓度的处理和每个浓度的对照均设置6个重复。
(4)去掉细胞上清，用PBS冲洗细胞三次，最后一次时吸干残留的PBS。加入400μl细胞培养基稀释的1,5-脱水山梨醇溶液，浓度分别为0μM(Mock)、100μM(处理一)、200μM(处理二)、300μM(处理三)、400μM(处理四)。37℃，5％CO 2的恒温培养箱中继续培养40h。
(5)去掉细胞上清，用PBS冲洗细胞三次，每孔加入400μl RI溶液，充分裂解细胞后，转移到1.5ml离心管中，-80℃冻存。
(6)取冻存的样品，用RNA提取试剂盒(货号AP-MN-MS-RNA-250，Axygen公司产品)提取RNA并用反转录试剂盒(Bio-Rad公司产品)将RNA反转录为cDNA。
(7)利用SYBR Green qPCR技术检测样品中的病毒载量，GAPDH值作为内参。计算公式如下：SARS-CoV-2/GAPDH mRNA Ratio＝2 (内参的Ct值-病 毒的Ct值)。
用于检测SARS-CoV-2的引物对如下：
上游引物：5’-AGAAGATTGGTTAGATGATGATAGT-3’(如序列表序列1所示)；
下游引物：5’-TTCCATCTCTAATTGAGGTTGAACC-3’(如序列表序列2所示)。
用于检测GAPDH基因的引物对如下：
上游引物：5’-AGCCTCAAGATCATCAGCAATG-3’(如序列表序列3所示)；
下游引物：5’-ATGGACTGTGGTCATGAGTCCTT-3’(如序列表序列4所示)。
结果如图5所示：与对照组相比，加入1,5-脱水山梨醇的ACE2-293T细胞病毒载量明显下降，且呈现剂量依赖性。
实施例6：1,5-脱水山梨醇在小鼠模型抑制SARS-CoV-2病毒复制
本实施例研究1,5-脱水山梨醇在小鼠模型中对SARS-CoV-2病毒复制的影响，设置0μM(对照)，溶剂为PBS；1,5-脱水山梨醇组，2.5M的1,5-脱水山梨醇溶解于PBS中。共2个浓度梯度的处理，具体步骤如下：
(1)实验前将6周龄的糖尿病小鼠麻醉，将含有200μl PBS或200μl含2.5M1,5-脱水山梨醇的渗透压缓释泵(Alzet公司产品)植入到糖尿病(db/db)小鼠皮下。
(2)10天后，用8000PFU的新冠病毒鼠适应株MASCp36鼻腔感染小鼠。
(3)感染前后，每天记录小鼠体重，共记录7天。体重计算方法：与初始体重的比率＝(当下小鼠体重-感染前小鼠体重)/感染前小鼠体重*100％。
(4)另外，在感染后第三天将小鼠安乐死，取肺、气管和鼻甲用于病毒载量的检测。每20mg组织加入到400μl RI溶液，充分研磨后-80℃冻存。
(5)取冻存的样品，用RNA提取试剂盒(货号AP-MN-MS-RNA-250，Axygen公司产品)提取RNA并用反转录试剂盒(Bio-Rad公司产品)将RNA反转录为cDNA。
(6)利用SYBR Green qPCR技术检测样品中的病毒载量，GAPDH值作为内参。计算公式如下：SARS-CoV-2/GAPDH mRNA Ratio＝2 (内参的Ct值-病 毒的Ct值)
用于检测SARS-CoV-2的引物对如下：
上游引物：5’-AGAAGATTGGTTAGATGATGATAGT-3’(如序列表序列1所示)；
下游引物：5’-TTCCATCTCTAATTGAGGTTGAACC-3’(如序列表序列2所示)。
用于检测GAPDH基因的引物对如下：
上游引物：5’-TCAACAGCAACTCCCACTCTTCCA-3’(如序列表序列3所示)；
下游引物：5’-ACCCTGTTGCTGTAGCCGTATTCA-3’(如序列表序列4所示)。
结果如图6所示：与对照组相比，补充1,5-脱水山梨醇的糖尿病小鼠体重显著高于对照小鼠，肺部、气管、鼻甲病毒载量显著低于正常小鼠。
上述对1,5-脱水山梨醇分别在Vero细胞、Caco-2细胞、ACE2-293T细胞和糖尿病小鼠中对SARS-CoV-2病毒的抑制效果的研究，表明1,5-脱水山梨醇可作为SARS-CoV-2病毒感染的防治候选药物。本发明对感染SARS-CoV-2病毒的治疗具有应用价值。
以上对本发明进行了详述。对于本领域技术人员来说，在不脱离本发明的宗旨和范围，以及无需进行不必要的实验情况下，可在等同参数、浓度和条件下，在较宽范围内实施本发明。虽然本发明给出了特殊的实施例，应该理解为，可以对本发明作进一步的改进。总之，按本发明的原理，本申请欲包括任何变更、用途或对本发明的改进，包括脱离了本申请中已公开范围，而用本领域已知的常规技术进行的改变。按以下附带的权利要求的范围，可以进行一些基本特征的应用。
工业应用
本发明通过对1,5-脱水山梨醇分别在Vero细胞、Caco-2细胞、ACE2-293T细胞中对SARS-CoV-2病毒的抑制效果的研究，发现了1,5-脱水山梨醇可作为SARS-CoV-2病毒感染的防治候选药物，1,5-脱水山梨醇有在作为SARS-CoV-2病毒感染防治候选药物中应用的价值。
Figure PCTCN2022091628-appb-000001
Figure PCTCN2022091628-appb-000002

Claims (10)

1,5-脱水山梨醇在制备预防和/或治疗SARS-CoV-2病毒所致疾病或SARS-CoV-2病毒感染的药物中的应用。
1,5-脱水山梨醇在制备SARS-CoV-2病毒抑制剂中的应用。
1,5-脱水山梨醇在制备抑制SARS-CoV-2病毒增殖或复制产品中的应用。
1,5-脱水山梨醇在制备抑制动物个体、动物器官、动物组织或动物细胞中SARS-CoV-2病毒增殖或复制产品中的应用。
SARS-CoV-2病毒抑制剂，其中：所述SARS-CoV-2病毒抑制剂的活性成分含有1,5-脱水山梨醇。
制备SARS-CoV-2病毒抑制剂的方法，其特征在于：所述方法包括将1,5-脱水山梨醇作为组分制备组合物，所述组合物为SARS-CoV-2病毒抑制剂。
药用化合物，其特征在于：所述药用化合物为1,5-脱水山梨醇。
根据权利要求7所述的药用化合物，其特征在于：所述药用化合物用于抑制SARS-CoV-2，或所述药用化合物用于预防和/或治疗SARS-CoV-2病毒所致疾病。
抑制SARS-CoV-2病毒感染动物的方法，包括给受体动物施用1,5-脱水山梨醇以抑制SARS-CoV-2病毒感染动物。
治疗或/和预防SARS-CoV-2病毒所致疾病的方法，包括给受体动物施用1,5-脱水山梨醇进行治疗或/和预防SARS-CoV-2病毒所致疾病。
PCT/CN2022/091628 2021-04-28 2022-05-09 1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用 WO2022228581A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110465681.9 2021-04-28
CN202110465681.9A CN114668754B (zh) 2021-04-28 2021-04-28 1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用

Publications (1)

Publication Number Publication Date
WO2022228581A1 true WO2022228581A1 (zh) 2022-11-03

Family

ID=82070280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/091628 WO2022228581A1 (zh) 2021-04-28 2022-05-09 1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用

Country Status (2)

Country Link
CN (1) CN114668754B (zh)
WO (1) WO2022228581A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478650A (zh) * 2015-08-26 2017-03-08 Sk新技术株式会社 使用水蒸气产生脱水糖醇的方法
CN111329998A (zh) * 2020-03-27 2020-06-26 广东天普生化医药股份有限公司 乌司他丁在制备防治重症新型冠状病毒肺炎药物中的用途
CN112255219A (zh) * 2020-10-12 2021-01-22 中拓生物有限公司 一种1,5-脱水山梨醇的测定试剂盒及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013075895A (ja) * 2011-09-16 2013-04-25 Kissei Pharmaceutical Co Ltd 尿路感染症の治療用医薬組成物
FR3030279B1 (fr) * 2014-12-17 2019-08-02 Tereos Starch & Sweeteners Belgium Composition antibacterienne contenant un melange isomerique de monoethers ou de monoacetals d'alkyle de monosaccharides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478650A (zh) * 2015-08-26 2017-03-08 Sk新技术株式会社 使用水蒸气产生脱水糖醇的方法
CN111329998A (zh) * 2020-03-27 2020-06-26 广东天普生化医药股份有限公司 乌司他丁在制备防治重症新型冠状病毒肺炎药物中的用途
CN112255219A (zh) * 2020-10-12 2021-01-22 中拓生物有限公司 一种1,5-脱水山梨醇的测定试剂盒及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG YING, ZHU TIE-HONG: "Significances of 1, 5 Anhydro-D-ghlcitol in Early Diagnosis of Diabetes", MEDICAL RECAPITULATE,, vol. 14, no. 7, 6 April 2008 (2008-04-06), CN , pages 1077 - 1079, XP055982627, ISSN: 1006-2084 *

Also Published As

Publication number Publication date
CN114668754B (zh) 2022-09-13
CN114668754A (zh) 2022-06-28

Similar Documents

Publication Publication Date Title
CN113967211B (zh) 盐酸石蒜碱硫酯在制备抗冠状病毒药物中的应用
CN113289018B (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
WO2021203704A1 (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
CN111374985B (zh) 盐酸非那吡啶的医药用途
CN112694463B (zh) 一种异戊烯基色原酮类化合物在制备抗冠状病毒药物中的用途
WO2024001265A1 (zh) 麦冬皂苷d在制备抗轮状病毒药物中的应用
WO2022228581A1 (zh) 1,5-脱水山梨醇在制备治疗和预防SARS-CoV-2病毒所致疾病药物中的应用
TWI605822B (zh) 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品
WO2022143710A1 (zh) 吡咯喹啉醌、其衍生物和/或盐作为抗病毒新药的用途及其药物组合物
CN110755436A (zh) 一种防治寨卡病毒感染的药物及石蒜碱在制备防治寨卡病毒感染的药物中的应用
CN113143924B (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
CN109864990A (zh) 巴利卡替在制备抗丝状病毒感染药物中的应用
CN112675172B (zh) 一种二酮哌嗪类化合物在制备抗冠状病毒药物中的用途
CN112245424B (zh) 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途
CN111920801A (zh) 表没食子儿茶素没食子酸酯在制备治疗和/或预防埃克病毒感染所致疾病的药物中的用途
CN111568900A (zh) 吲哚美辛在抗冠状病毒感染中的应用
CN106860437B (zh) 双细辛酮i作为治疗登革病毒感染的药物及其制药用途
Moscato et al. A retrospective study on two cohorts of immunocompetent women treated with nonavalent HPV vaccine vs. Ellagic acid complex: outcome of the evolution of persistent cervical HPV infection.
CN113197894B (zh) 奥巴托克在制备广谱抗冠状病毒药物中的应用
CN113750083B (zh) 二甲双胍在制备治疗手足口病的药物中的应用
EP3960173A1 (en) Enterovirus inhibitor
CN114712342B (zh) 紫草酸在制备抗流感病毒药物中的应用
CN112353809B (zh) 一种黄芪甲苷类化合物的药物用途
CN116236580B (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
CN114767671B (zh) Ver-49009在制备预防和/或治疗腺病毒感染的药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22795050

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22795050

Country of ref document: EP

Kind code of ref document: A1